Moneycontrol
Last Updated : Oct 05, 2018 12:02 PM IST | Source: Moneycontrol.com

Cadila Healthcare rises nearly 2% on EIR from USFDA

The plant had completed the USFDA audit from August 14 to 24, 2018 with Zero 483 observations.

Moneycontrol News @moneycontrolcom
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Shares of Cadila Healthcare rose nearly 2 percent in the early trade on Friday after company received EIR from USFDA for its Ahmedabad unit.

The company's Biologics manufacturing facility (Zydus Biologics) located at the Zydus Biotech Park in Ahmedabad has received an EIR (Establishment Inspection Report) from the USFDA signifying the successful closure of the audit.

The plant had completed the USFDA audit from August 14 to 24, 2018 with Zero 483 observations.

Zydus Cadila has received the final approval from the USFDA in market Exemestane Tablets, 25 mg. It will be manufactured at the group‘s formulations manufacturing facility at SEZ, Ahmedabad.

The estimated sale for Exemestane Tablets is USD 68.6 million.

At 09:17 hrs Cadila Healthcare was quoting at Rs 386.20, up Rs 3.50, or 0.91 percent.

For more market news, click here

Posted by Rakesh Patil
First Published on Oct 5, 2018 09:20 am
Loading...
Sections
Follow us on
Available On